The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Her2-positive Breast Cancer
-
Age: Between 18 - 100 Years
-
Gender: Female
-
Other Inclusion Criteria:
1) ECOG Performance Status 0-1. 2) Adequate hepatic, renal, and bone marrow function. 3)Not pregnant and not nursing.
You may not be eligible for this study if the following are true:
-
1) Patients with known active and/or untreated Hepatitis B or Hepatitis C or chronic liver disease are ineligible. 2) History of any prior (ipsi- or contralateral) invasive breast cancer within 3 years of registration. 3) Evidence of recurrent disease following preoperative therapy and surgery. 4) History of exposure to the following cumulative doses of anthracyclines: Doxorubicin > 240 mg/m2; Epirubicin or Liposomal Doxorubicin-Hydrochloride (Myocet®) > 480 mg/m2. For other anthracyclines, exposure equivalent to doxorubicin > 240 mg/m2.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
